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Abstract 
One of the primary objectives of physiologically based pharmacokinetics (PBPK) is the prediction of a drug’s 
pharmacokinetics just from knowledge of its physicochemical structure. Unfortunately, at present, the 
accuracy of this prediction is limited for most drugs because of uncertainty about the drug’s organ/blood 
partition coefficient (K). However, there are two classes of solutes which are exceptions to this: 1) the 
highly lipid soluble (HLS) solutes, and 2) the extracellular (ECS) solutes. Since the HLS drugs (eg, volatile 
anesthetics, propofol, cannabinol) have lipid/water partition coefficients (PL/W) of 100 or greater, their K is 
dominated by the tissue fat fraction and one can accurately predict K just from in vitro measurements of 
PL/W along with prior anatomic measurements of the fat fraction of the organs in the PBPK model. Since the 
ECS drugs, such as most antibiotics, cannot penetrate cells, they are not subject to the intracellular binding 
that complicates the prediction of K for the weak bases and acids. The ECS K is determined primarily by 
plasma and interstitial albumin binding and can be predicted from in vitro measurements of plasma 
albumin binding along with prior measurements of interstitial tissue volume and albumin concentrations. 
This review provides an in depth discussion of the PBPK modeling of these two drug classes along with 
many specific clinical examples illustrating the good PBPK predictions possible with just zero (volatile 
anesthetics) or 1 (the clearance) adjustable parameter. The PBPK analysis uses PKQuest, a freely 
distributed, general purpose pharmacokinetic program. PKQuest is designed so that application to the HLS 
and ECS solute classes is especially easy. The user only needs to enter the specific parameters that are 
required to characterize the drug (eg, PL/W for HLS or plasma albumin binding for ECS) with all the other 
PBPK parameters (organ blood flow, fat fraction, extracellular volumes, etc.) are set by default. 
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Introduction 
The standard well-stirred, flow-limited PBPK differential equation describing the solute balance of organ 
i is deceptively simple [1]: 
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where Fi is the organ blood flow, CA(t) is the arterial blood concentration and Ci(t) is the venous blood 
concentration leaving the organ and it is assumed that the free, unbound well-mixed tissue concentration 
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is equal to the free concentration in the venous blood of the organ. All the complexity is in the parameter 
V
i
 which is the organ “volume of distribution” defined by: 
 
i i
i i i i i i i i
B T T B T






V C V C C V K V
V K V






i are the anatomic blood and extravascular organ volumes, respectively, CT
i is the tissue 
concentration and Ki (= CT
i/Ci) is the tissue/blood partition coefficient. The organ blood flow (Fi) and the 
blood (VB
i
) and tissue (VT
i
) volumes can be accurately estimated from prior human physiological and 
anatomic measurements. However, K
i
, which depends on the specific physicochemical properties of the 
solute and varies from values of 0.2 or less to greater than 100, dominates the kinetics and is the major 
uncertainty and limitation of PBPK analysis. 
In general, for an accurate PBPK analysis it is necessary to determine the K
i
 for the solute of interest 
from complex animal (usually rat) tissue measurements and then assume (hope) that the rat values can be 
extrapolated to the human. Ideally, one would like to be able to predict Ki just based on its chemical 
structure, allowing one to determine a drug’s detailed PK a priori. Unfortunately, for the majority of drugs 
that are weak acids or bases, it is not, as yet, possible to predict Ki accurately enough to meet this ideal. 
The current state of the art in predicting K
i
 is illustrated by the algorithm developed by Poulin and 
colleagues over many years of analysis [2]. About 50 % of the predictions are accurate to within a factor of 
2, with about 15 % of the predictions off by a factor of greater than 3 fold. Although this level of accuracy is 
useful for, eg, predicting preliminary dosage levels for a trial drug, it severely limits the value of PBPK 
predictions because they are unlikely to be superior to those made using just a simple 1-compartment 
model based just on the standard pharmacokinetic (PK) measurements of clearance and volume of 
distribution. 
However, there are two major exceptions to this limitation: the highly lipid soluble (HLS) and the 
extracellular drugs (ECS). The HLS drugs (volatile anesthetics, propofol, cannabinol, etc.) have lipid/water 
partition coefficients (PL/W) of 100 or greater and their K
i
 is dominated by the tissue fat fraction [1]. This 
means that one can predict the Ki just from in vitro measurements of PL/W along with previous 
measurements of the fat fraction of all the tissues in the PBPK model (see Fig. 1). The ECS drugs, such as 
most antibiotics, cannot penetrate cells, and therefore are not subject to the intracellular binding that 
complicates the prediction of Ki for the weak bases and acids. The Ki of most ECS drugs is determined 
primarily by the volume and albumin concentration in the interstitial space and the albumin binding 
affinity. Thus, the ECS Ki can be predicted from prior measurements of tissue interstitial volumes and 
albumin concentrations and in vitro measurements of albumin binding affinity.  
PKQuest is a freely distributed (www.pkquest.com), Java based, PK and PBPK program. The major effort 
in its design has been to provide a user interface that is both simple enough to be used by students as an 
adjunct in PK courses and general enough to be applicable to most PK and PBPK applications. Since its 
introduction in 2002, PKQuest has been applied to hundreds of solutes described in more than 11 
publications [3-13]. Recently, a freely distributed textbook (“Computer assisted human pharmacokinetics”) 
has been developed that covers most PK topics and is closely integrated with PKQuest[1]. 
PKQuest implements the standard PBPK approach. The body is divided into 14 “tissue” compartments 
(Fig. 1), each of which is described by Eqs. (1) and (2) and three “tissue” parameters (VT
i, Fi, and Ki). For a 
given solute input (oral, IV, etc.) the set of equations is solved numerically, and a plot of the time 
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dependent solute concentration for each of the organs is plotted. Usually, of particular interest, is the time 
dependence of the concentration in the “vein” compartment.  
 
Figure 1.  PBPK model used in PKQuest. The body is modeled by 12 tissue regions, arranged in parallel (except 
for the “portal” and “lung” tissue which are in series) connected by the “vein” and “artery” compartments. 
The tissue “portal” refers to the stomach, small and large intestine, spleen and pancreatic organs. The tissue 
parameters are listed in Table 1. 
In general, PBPK modeling requires input of a standard set of the 28 tissue volume (VTi) and blood flow 
(Fi) parameters. In PKQuest, a “standard human” set of these parameters has been refined by application 
of PKQuest to hundreds of solutes with varying properties. For example, the muscle blood flow was 
determined from the PK of D2O and the adipose blood flows from the PK of the volatile anesthetics (see 
below). These “standard human” values are listed in Table 1 (in PKQuest, the default units are minutes, 
liters and kilograms). Since these are the default background values, the user does not need to be 
concerned with supplying them. Of course, PKQuest allows these values to be varied in the more general 
case. 
One of the novel features of PKQuest is that it is designed so that the PBPK modeling of HLS and ECS 
solutes can be run by entering just the minimum set of adjustable parameters (body fat fraction, PL/W, 
albumin binding, etc.) with all the other required human parameters as standard defaults. In addition to 
potentially predicting the PK of unknown solutes, this PBPK application is of heuristic value in, for example, 
teaching nurse anesthetists how the PK of volatile anesthetics depends on, e.g. respiratory rate. The 
following two sections will review the PK of these two solute classes along with clinical examples of the 
application of PKQuest to specific solutes. 
Highly lipid soluble solutes (HLS) 
For an ideal HLS solute, the tissue/blood partition Ki is determined entirely by the lipid fraction of the 
tissue (fL
i) and blood (fL
B) and the lipid/water partition fraction (PL/W) [1]: 
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Equation (3) assumes that the blood HLS binding is due entirely to the blood lipid fraction (fL
B
). In humans, 
the directly measured fL
B
 is about 0.005 [12]. However, using this value often underestimates the blood 
HLS binding because there is additional plasma HLS binding, primarily by albumin. The procedure used in 
PKQuest is to input the in vitro measurement of the “free plasma fraction” if it is known and then use this 
value to estimate the apparent fL
B. If it is not known, the default fL
B of 0.015 (Table 1) provides a rough 
starting estimate and it is then treated as an adjustable parameter.   
Table 1.  Organ PBPK parameters for the standard 20 % fat, 70 kg human. The organ “portal” 
refers to all the organs drained by the portal vein (eg, GI tract, spleen, pancreas). The organs 
“tendon” and “other” represent poorly characterized, low flow connective tissues. The 
adipose and adipose 2 organ weights (assumed equal) are adjusted for the individual’s body 
fat fraction. The ECF fraction is the fraction of the non-lipid organ weight that is extracellular. 
KAlb is the ratio of the albumin concentration in the EDTA interstitial space relative to the 
plasma albumin. 
Organ Weight (kg) 
Perfusion 
(l/min/kg) 
Lipid Fraction ECF fraction KAlb 
vein 4.29 1.0 0.015 0.595 NA 
artery 1.21 0.0 0.015 0.595 NA 
liver 1.8 0.25 0.02 0.23 0.5 
portal 1.5 0.75 0.016 0.3 0.35 
kidney 0.31 4.0 0.0136 0.165 0.35 
brain 1.4 0.56 0.0176 0 0.1 
heart 0.33 0.8 0.0136 0.264 0.5 
muscle 26.0 0.0225 0.0136 0.15 0.5 
skin 2.6 0.1 0.0136 0.6 0.25 
lung 0.536 -1.0 0.0136 0.2 0.35 
tendon 3.0 0.01 0.0136 1 0.25 
other 5.522 0.02 0.0136 0.2 0.25 
adipose 8.758 0.074 0.8 1 0.35 
adipose 2 8.758 0.01408 0.8 1 0.35 
Bone 4.0 0.0 0 0 0 
The volatile anesthetics represent the ideal HLS because they are relatively inert, have negligible specific 
tissue binding and, in most cases, are not metabolized with their clearance determined solely by the 
respiration rate and blood/gas partition. Thus, their PK can be predicted using the HLS PBPK model along 
with in vitro measurements of oil/water, blood/water and air/water partition coefficients with no 
adjustable individual subject parameters. For the volatile anesthetics there are detailed measurements of 
the oil/water, air/water, blood/gas and various tissue partition coefficients (Ki), all of which are 
qualitatively consistent with Eq. (3). 
The PBPK parameter that dominates the PK of the HLS is the adipose tissue volume and blood flow. It is 
essential that the magnitude of the heterogeneity (if any) of adipose blood flow is included in the PBPK 
model. The time constant (T) for adipose tissue equilibration is described by (assuming a well-mixed, flow 
limited tissue):  






T   (4) 
The units are kg for Adipose weight, and kg/min for blood flow while the adipose/blood partition is 
dimensionless.  
For the volatile anesthetics T ranges from about 500 min to 3 days. At early times (several hours) before 
the lipid becomes saturated, the adipose tissue behaves like an infinite sink and the PK is not dependent on 
the heterogeneity. It is only at times that are long relative to T that the heterogeneity becomes apparent. 
Thus, in order to determine adipose perfusion heterogeneity it is necessary to have PK measurements that 
extend to days. Probably the best available set of measurements of this kind is the remarkable series of 
studies of the PK of the volatile anesthetics isoflurane, sevoflurane and desflurane by Eger and colleagues 
[14, 15]. They measured the ventilation rate and the inspired, mixed and end tidal gas concentration for 6 
days following a 30 minute uptake in normal volunteers. Dr. Eger kindly provided this data which was then 
modeled using PKQuest to estimate the adipose perfusion heterogeneity. The analysis indicated that at 
least two equal volume adipose compartments with perfusion rates of 0.074 and 0.014 l/kg/min were 
needed to accurately model the long time data[10] and these are the default values in PKQuest (Table 1).  
 
Figure 2.  PKQuest interface. The top panel lists all the input required to specify the PBPK pharmacokinetics 
for isoflurane (see text for details). 
Figure 2 shows the interactive PKQuest interface for isoflurane. The isoflurane kinetics are completely 
characterized by the entries in the top panel. The check box “Volatile” turns on the PBPK for volatile 
solutes (which are, presumably, also HLS). Setting Kbair, Kwair, Kfwat characterizes isoflurane. The 
parameters Vent (alveolar ventilation) and Vol (alveolar volume) are the standard 70 kg human values. The 
entries in the other panels describe the details of the dose regimen and the variables that should be 
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plotted in the output.  
Figures 3 and 4 show semi-log plots of the PKQuest PBPK prediction of the short and long time expired 
partial pressure (PExpired) relative to the PInspired during the 30 minute uptake period for isoflurane, 
sevoflurane and desflurane. It can be seen that, although these 3 anesthetics have significantly different 
properties (blood/air and oil/air partition), the human PK can be accurately fit using the same default PBPK 
model with no adjustable parameters. PBPK analysis is ideally suited for modeling the volatile anesthetics 
and has clear advantages over the 5 compartment mammillary model with 10 adjustable parameters that 
is classically used for these solutes [14, 15].  
 
Figure 3.  PKQuest PBPK predictions (black line) of short time pharmacokinetics of isoflurane, sevoflurane and 
desflurane using the identical basic PBPK model with two equal weight adipose organs with blood perfusions 
of 0.014 and 0.074 l/kg/min. IsofluraneS and IsofluraneD refer to two different sets of data. 
This same set of PBPK organ parameters is also applicable to non-volatile HLS. Figure 5 shows the 
PKQuest interface top panel for cannabinol. The “Fat/water partition” check box turns on the HLS option. 
Cannabinol has a very high oil/water partition of about 200,000 [10] (input in the “Kfwat” box.). Only two 
adjustable parameters were required to provide a good fit to the PK data of Johansson et. al. [16]: the 
fractional liver clearance (0.651) and the blood fat fraction (0.0075). Figure 6 is the PKQuest output 
showing the PKQuest fit to this data. 
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Figure 4.  PKQuest PBPK predictions (black line) of long time pharmacokinetics of isoflurane, sevoflurane and 
desflurane using the identical basic PBPK model with two equal weight adipose organs with blood perfusions 
of 0.014 and 0.074 l/kg/min. IsofluraneS and IsofluraneD refer to two different sets of data. 
 
Figure 5. Top panel of the PKQuest interface for cannabinol (see text for details) 
An important clinical application of the PBPK HLS model is in predicting the PK of anesthetics in obese 
subjects. The prediction is obtained simply by changing the “Fat fr” entry in the PKQuest interface (Figs. 2 
and 5). Figures 7 and 8 show two examples obtained from the PKQuest analysis of propofol [17]. Servin et. 
al. [18] had previously shown that the “eye opening” time following a 180 minute propofol infusion was 
shorter in obese subjects (10.3 min) versus normal weight subjects (18.4 min). Figure 7 shows that the 
PBPK model provides a similar prediction. Propofol is routinely used for long term sedation. Figure 8 shows 
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the arterial concentration during the washout period following a 10 day constant infusion. It can be seen 
that in obese subjects (red) the washout is markedly slower with a greatly prolonged waking time. In 
determining the PK for the obese subjects, it is assumed that the standard human tissue parameters, 
including those for “Adipose1” and “Adipose2” (Table 1) can be extrapolated to the obese subjects. This is 
a major limitation because a careful evaluation of these parameters is not available for these subjects.  
 
Figure 6.  PKQuest PBPK predictions (red line) of pharmacokinetics of cannabinol 
 
Figure 7. Plot of arterial blood propofol concentration in normal weight (black) and morbidly obese subjects 
(red) following a 180 minute propofol infusion.  At a time of 180 minutes, the constant propofol infusion is 
terminated. The time for the arterial level to drop below the “eye opening concentration” is about 5 minutes 
for the obese and 13 minutes for the normal subjects 
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Figure 8. Comparison of arterial propofol concentration in normal (black) and obese (red) subjects during 
washout following a 10 day (14,400 minutes) constant infusion. The constant infusion rate has been adjusted 
so that the concentrations at the end of the 10 day period are identical for the normal and obese subjects. 
The extreme limit of HLS solutes are the persistent organic pollutants (POP), such as dioxins and 
polychlorinated biphenyls, which are characterized by human life times of several years and have 
lipid/water (PL/W) partition ranging from 10
5
 to greater than 10
7
 [12]. Because of these long lifetimes and 
the near impossibility of obtaining accurate experimental human PK data, POP modeling and prediction has 
become one of the most important PBPK applications. There is a common misperception that the long 
lifetimes results, primarily, from their very high lipid partition and resultant slow adipose tissue washout 
[19]. What is not commonly recognized is that, as described in eq. (3), for PL/W greater than about 1000, 
KAdipose reaches a maximum value equal to fL
Adipose/fL
Blood, and further increases in PL/W do not increase it 









    (5) 
Substituting this relation for the maximum value of KAdipose into eq. (4), the longest possible time constant 
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
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where FAdipose is the adipose perfusion rate. Thus, high lipid partition can only account for washout time 
constants of about 11 days, much shorter than the year or more that is observed for many POPs. 
One possible explanation is that Eq. (6) is incorrect because it assumed that the adipose/blood 
exchange is flow limited, while, as clearly shown by Levitt [12], it becomes diffusion limited for some POPs. 
This diffusion limitation arises because the high PL/W of the POP produces such a low free water 
concentration that diffusion through the capillary wall becomes rate limiting. However, even taking 
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account of this diffusion limitation, the adipose exchange time constant is at least 10 fold shorter than the 
POP lifetimes and cannot be responsible for the observed human POP persistence [12].  
The explanation of this discrepancy between the adipose POP time constant and the whole body human 
time constant is simply that the PK of the POPs are limited by their extremely low rate of metabolism and 
excretion, not by the adipose/blood exchange. As the lipid partition increases, the free water 
concentration in the blood decreases and, presumably, the rate of liver metabolism decreases 
proportionally. If the metabolic time constant for excretion is long compared to the time constant for 
adipose and other tissue exchange, then at long times, one can ignore the PBPK model details and the 
plasma concentration can be described by a simple 1-compartment model characterized by its clearance 
(Cl) and volume of distribution (V): 
 /( / )( ) ( / )e ( / )e /  Clt TCl V t ClC t D V D V T V Cl  (7) 
where D is the dose and TCl is the metabolic (ie, liver) time constant. Although the detailed PBPK model is 
required to describe the short time PK of the POPs, at long times the PK depends only on the liver 
clearance and is independent of the kinetics of solute exchange in the peripheral tissues. 
This is quantitatively illustrated using the PBPK cannabinol model described above [12]. Figure 9 shows 
a comparison of the plasma cannabinol concentration for the PBPK (black line) versus the 1-compartment 
model (red line) as the metabolic time constant (TCl) increases from 1.25 days (top panel) to 125 days 
(bottom panel). It can be seen (bottom panel) that when the metabolic excretion rate becomes rate 
limiting (TCl = 125 days >> TAdipose =11 days), the one compartment model provides a good prediction of the 
PK after the initial ≈11 day transient period when the adipose tissue exchange is limiting. 
Extracellular solutes (ECS) 
Because the ECS, by definition, do not enter cells, they are not subject to the poorly characterized 
intracellular binding that confounds predictions of the K
i
 for the typical weak acid or base. Since the ECS 
solutes are confined to the plasma and interstitial space, the basic PBPK equations described above (eqs. 
(1) and (2)) are modified as follows: 
 
i
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EC P P P
i i i i
EC P EC ECT
d ( )
[C ( ) ( )]
C t
V F t C t
dt





i is the organ plasma flow, CP
A is the plasma arterial concentration, and CP
i is the venous plasma 
concentration. The ECS volume of distribution (VEC
i) is defined in terms of the anatomical plasma (VP
i) and 
interstitial (VECT
i) volumes and the ECS interstitial/plasma partition coefficient (KEC
i). Because both the 
plasma and interstitial ECS binding is dominated by the plasma and interstitial albumin, it can be shown [7] 
that the ECS partition coefficient (KEC
i) can be described by: 
 i i iEC Alb P Alb(1 )K K f K     (9) 
where KAlb
i is ratio of interstitial/plasma albumin concentration in organ i and fP is the fraction of the ECS 
solute that is free (unbound) in plasma and characterizes the ECS albumin binding affinity. If fp = 1 (no 
albumin binding), KEC
i = 1. If fp = 0 (very high affinity binding), KEC
i = KAlb
i.  
Levitt [7] has carried out a detailed review of the literature and determined an optimal set of values for 
KAlb
i (the ratio of interstitial/plasma albumin concentration) and the fraction of each organ that is 
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extracellular (ECF fraction) with VECT
i
 (the anatomic interstitial volume for each organ i) equal to the ECF 
fraction times the total organ volume. These parameters are listed in Table 1 and are the default 
parameters in PKQuest. Using these predetermined values, the only parameter that is solute specific is fp 
(the free solute fraction in plasma) and this can be determined from in vitro measurements. Thus, all of the 
parameters in Eqs. (8) and (9) can be determined a priori, providing a complete description of the ECS 
PBPK.   
 
Figure 9. Comparison of 1-compartment (red) vs PBPK (black) model for HLS (eg, cannabinol) with an adipose 
time constant of about 11 days. As the metabolic time constant (ie, liver clearance) increases from 1.25 days 
(top), to 12.5 (middle) to 125 days (bottom), the PBPK model approaches the 1-compartment model at times 
longer than 11 days. 
For most ECS, there is only one adjustable parameter, the clearance (usually renal). Figure 10 shows the 
top panel of the PKQuest interface for amoxicillin. The “Extracellular” check box turns on the ECS PBPK 
model. The “freepl” is the fraction free in plasma (= fP), which characterizes both the plasma and interstitial 
albumin binding. The only adjustable parameter is the “Renal Clr” which is set to 0.353 (the fraction of 
ADMET & DMPK 7(1) (2019) 60-75 Lipid soluble and extracellular solutes 
doi: 10.5599/admet.579 71 
renal plasma cleared). Note also that the “Cap perm” is set to 1.0, indicating infinite capillary permeability 
(see below). Figure 11 shows the good fit of the PKQuest PBPK prediction to the experimental data of 
Arancibia et. al.[20] following a bolus IV input. For some solutes the plasma albumin binding (= freepl) is 
poorly characterized or variable, and one treats freepl as another adjustable model parameter. Using this 
identical PBPK model, similarly good fits were obtained to the experimental PK measurements for the ECS 
solutes EDTA, DTPA, morphine-6-glucuronide, morphine-3-glucuronide, mannitol and for the β-lactam 
antibiotics amoxicillin, piperacillin and cefatrizine [7]. 
 
Figure 10. Top panel of PKQuest interface showing the parameters that characterize amoxicillin PBPK 
pharmacokinetics (see text for details). 
For all the solutes discussed above, the standard PBPK “flow-limited, well-stirred” model has been 
assumed for the tissue PK. This assumes that the free, unbound concentration in the tissue space is 
uniform for the entire tissue and is equal to the free plasma concentration that leaves the organ in the 
vein. This assumes, in essence, that the capillary permeability is infinite. This assumption may be incorrect 
because the ECS solutes cannot penetrate cell membranes and must traverse the capillary wall through the 
potentially limiting interendothelial slits [21].  
 
Figure 11. Semi-log plot of comparison of experimental antecubital amoxicillin concentration (blue circles) 
and PKQuest PBPK predicted antecubital concentration (red line) following a bolus IV input. 
There is no question that some ECS solutes have a capillary permeability limitation. The classical 
example is inulin, whose capillary permeability has been determined in animal models using a variety of 
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experimental approaches [21]. PKQuest has been modified to allow for a capillary permeability limitation 
characterized by the parameter “flcr”, the fraction of plasma solute that equilibrates with the interstitial 

















 are the free unbound concentrations in the artery, vein and tissue, respectively. If the 




 and fclr = 1. If the permeability is 0, cA =cv and fclr = 0. In PKQuest, 
the input parameter “Cap perm” (Fig. 9) is the fclrmuscle. The flcr of the other tissues are then set equal to 
proportional values determined from a literature review [7]. Figure 12 shows a comparison of the 
permeability limited (top panel) versus infinite permeability (bottom panel) PKQuest PBPK fit to the inulin 
data of Odeh et al. [22]. It can be seen that although the permeability limitation only affects the early time 
data and is a relatively small effect, the addition of the limitation clearly improves the fit. The best fit was 
obtained with the fclrmuslc of 0.45 which corresponds to a capillary permeability (PS, eq. (11)) of skeletal 
muscle of 0.61 ml/min/100 gm, similar to that determined directly in animal studies [21]. This PBPK 
approach represents a new way to study capillary permeability and is the first human measurement of 
muscle capillary permeability for these solutes.  
 
Figure 12.PKQuest PBPK pharmacokinetics (red line) for inulin following a 5 minute constant IV infusion. The 
top panel is with a capillary permeability limitation (fclr
muscle
 = 0.45) and the bottom panel is for an infinite 
permeability (fclr
muscle
 = 1). 
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It had not been previously recognized that, as the albumin binding affinity increases, the capillary 
permeability should decrease. One can show that the parameter fclr
i
 is described by the relation [3,4,7]:  
 
i i ifclr 1 exp( / )pf PS F    (11) 





 are the capillary surface area and flow rate for tissue i. As P approaches infinity, fclr approaches 1 
and the solute becomes flow limited. It can be seen that solutes that have a high “intrinsic” P if they are 
unbound, may become capillary limited as the albumin binding affinity increases and fp approaches zero. 
This fp dependence of the capillary permeability was tested using the experimental PK of a series of β-
lactam antibiotics with fp varying from 0.8 for amoxicillin, to 0.52 for piperacillin, to 0.07 for flucloxacillin 
and 0.03 for dicloxacillin [7]. The quality of the PKQuest PBPK fits to the experimental data with and 
without a capillary permeability limitation was compared. For flucloxacillin and dicloxacillin, the two 
solutes with the highest albumin binding, the fit clearly improved when a permeability limitation was 
introduced. Figure 13 shows a comparison of the PKQuest output for dicloxacillin with a permeability 
limitation (top panel, fclr
muscle
 = 0.3) versus infinite permeability (bottom panel, fclr
muscle
 = 1). Again it can be 
seen that although the permeability limitation only affects the early time data and is a relatively small 
effect, the addition of the limitation clearly improves the fit. The estimated PBPK human PS values are 
similar to those of EDTA and mannitol, ECS solutes of similar size, measured directly in the cat [7].  
 
Figure 13.PKQuest PBPK pharmacokinetics (red line) for dicloxacillin following a 30 minute constant IV 
infusion. The top panel is with a capillary permeability limitation (fclr
muscle
 = 0.3) and the bottom panel is for 
an infinite permeability (fclr
muscle
 = 1). 
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The possibility of a capillary permeability limitation complicates the PK of the ECS solutes. As shown 
above, for solutes the size of the β-lactam antibiotics and fp greater than 0.3, it can be assumed that the 
permeability is infinite. For larger solutes (eg, inulin) or higher albumin binding affinity (eg, dicloxacillin), 
there may be significant permeability limitation that can be modeled by treating the PKQuest capillary 
permeability parameter “fclr” as an additional adjustable parameter. 
Conclusion 
It is clear from the above discussion that the HLS and ECS represent the ideal solutes for PBPK analysis. 
The PK of these solutes can usually be accurately predicted using only zero (volatile anesthetics) or one 
adjustable parameter (the clearance). Not only can one predict the blood or plasma PK, but having so few 
adjustable parameters increases ones confidence in the PBPK model, allowing the determination of the 
time dependent concentration in the different tissues and how the PK varies with, eg, exercise or body fat 
fraction. Unfortunately, the HLS and ECS solutes classes are limited, with the examples discussed above 
nearly exhausting the important drug classes. In contrast, for the much more common weak acid or base 
solutes, an accurate PBPK model requires detailed animal experimental measurement of the individual 
organ Ki, and then an uncertain extrapolation to the human. These factors have significantly limited the 
confidence in the use of PBPK models for, eg, toxicological applications [23]. It does not seem to be widely 
recognized that the HLS and ECS solutes are important exceptions to the usual problems associated with 
PBPK analysis and it is hoped that this discussion will remedy this. 
This discussion has focused on only one aspect of PKQuest: the PBPK analysis of the HLS and ECS 
solutes. PKQuest also offers several other novel PBPK features, including: 1) the first incorporation of the 
use of antecubital vein sampling in a PBPK model [9]; and 2) the first ethanol PBPK model with a rigorous 
definition of the non-linear bioavailability [6]. In addition to the PBPK module, PKQuest also has a number 
of other PK features. There is major emphasis on deconvolution which is a powerful and underutilized 
modeling approach. There are 6 different deconvolution routines available, each with its strengths and 
limitations. One novel deconvolution application is a general approach to determine the intestinal 
permeability during normal human drug absorption, with application of this approach to 90 different drugs 
[13]. All of these features are discussed with detailed worked examples in the freely distributed textbook 
“Computer assisted human pharmacokinetics” [1]. It is hoped that the interested reader will download the 
free software and textbook from www.pkquest.com and try out these and other PKQuest PK features.  
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